189 related articles for article (PubMed ID: 24352446)
1. Hepatitis C virus impairs natural killer cell-mediated augmentation of complement synthesis.
Kim H; Bose SK; Meyer K; Ray R
J Virol; 2014 Mar; 88(5):2564-71. PubMed ID: 24352446
[TBL] [Abstract][Full Text] [Related]
2. HBsAg stimulates NKG2D receptor expression on natural killer cells and inhibits hepatitis C virus replication.
Wang XX; Pan XB; Han JC; Cong X; Jin Q; Kong XS; Wei L; Feng B
Hepatobiliary Pancreat Dis Int; 2018 Jun; 17(3):233-240. PubMed ID: 29625837
[TBL] [Abstract][Full Text] [Related]
3. Contradicting roles of miR-182 in both NK cells and their host target hepatocytes in HCV.
El Sobky SA; El-Ekiaby NM; Mekky RY; Elemam NM; Mohey Eldin MA; El-Sayed M; Esmat G; Abdelaziz AI
Immunol Lett; 2016 Jan; 169():52-60. PubMed ID: 26518141
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus (HCV) evades NKG2D-dependent NK cell responses through NS5A-mediated imbalance of inflammatory cytokines.
Sène D; Levasseur F; Abel M; Lambert M; Camous X; Hernandez C; Pène V; Rosenberg AR; Jouvin-Marche E; Marche PN; Cacoub P; Caillat-Zucman S
PLoS Pathog; 2010 Nov; 6(11):e1001184. PubMed ID: 21085608
[TBL] [Abstract][Full Text] [Related]
5. Activation of natural killer cells by hepatitis C virus particles in vitro.
Farag MM; Weigand K; Encke J; Momburg F
Clin Exp Immunol; 2011 Sep; 165(3):352-62. PubMed ID: 21682720
[TBL] [Abstract][Full Text] [Related]
6. Autocrine/paracrine IL-15 that is required for type I IFN-mediated dendritic cell expression of MHC class I-related chain A and B is impaired in hepatitis C virus infection.
Jinushi M; Takehara T; Tatsumi T; Kanto T; Groh V; Spies T; Suzuki T; Miyagi T; Hayashi N
J Immunol; 2003 Nov; 171(10):5423-9. PubMed ID: 14607946
[TBL] [Abstract][Full Text] [Related]
7. Interferon α-stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1.
Stegmann KA; Björkström NK; Ciesek S; Lunemann S; Jaroszewicz J; Wiegand J; Malinski P; Dustin LB; Rice CM; Manns MP; Pietschmann T; Cornberg M; Ljunggren HG; Wedemeyer H
J Infect Dis; 2012 May; 205(9):1351-62. PubMed ID: 22457290
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia impairs anti-viral activity of natural killer (NK) cells but has little effect on anti-fibrotic NK cell functions in hepatitis C virus infection.
Wolter F; Glässner A; Krämer B; Kokordelis P; Finnemann C; Kaczmarek DJ; Goeser F; Lutz P; Nischalke HD; Strassburg CP; Spengler U; Nattermann J
J Hepatol; 2015 Dec; 63(6):1334-44. PubMed ID: 26297916
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C virus proteins inhibit C3 complement production.
Mazumdar B; Kim H; Meyer K; Bose SK; Di Bisceglie AM; Ray RB; Ray R
J Virol; 2012 Feb; 86(4):2221-8. PubMed ID: 22171262
[TBL] [Abstract][Full Text] [Related]
10. Cell-to-cell contact with hepatitis C virus-infected cells reduces functional capacity of natural killer cells.
Yoon JC; Lim JB; Park JH; Lee JM
J Virol; 2011 Dec; 85(23):12557-69. PubMed ID: 21937646
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity.
Oliviero B; Mantovani S; Varchetta S; Mele D; Grossi G; Ludovisi S; Nuti E; Rossello A; Mondelli MU
J Hepatol; 2017 Jun; 66(6):1130-1137. PubMed ID: 28192188
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus impairs natural killer cell activity via viral serine protease NS3.
Yang CM; Yoon JC; Park JH; Lee JM
PLoS One; 2017; 12(4):e0175793. PubMed ID: 28410411
[TBL] [Abstract][Full Text] [Related]
13. Immunological changes in different patient populations with chronic hepatitis C virus infection.
Szereday L; Meggyes M; Halasz M; Szekeres-Bartho J; Par A; Par G
World J Gastroenterol; 2016 May; 22(20):4848-59. PubMed ID: 27239111
[TBL] [Abstract][Full Text] [Related]
14. NKG2D functions as an activating receptor on natural killer cells in the common marmoset (Callithrix jacchus).
Watanabe M; Kudo Y; Kawano M; Nakayama M; Nakamura K; Kameda M; Ebara M; Sato T; Nakamura M; Omine K; Kametani Y; Suzuki R; Ogasawara K
Int Immunol; 2014 Nov; 26(11):597-606. PubMed ID: 24860119
[TBL] [Abstract][Full Text] [Related]
15. Soluble MICA-NKG2D interaction upregulates IFN-γ production by activated CD3-CD56+ NK cells: potential impact on chronic graft versus host disease.
Boukouaci W; Al-Daccak R; Dulphy N; Lauden L; Amokrane K; Fortier C; Marzais F; Bennabi M; Peffault de Latour R; Socie G; Toubert A; Charron D; Krishnamoorthy R; Tamouza R
Hum Immunol; 2013 Dec; 74(12):1536-41. PubMed ID: 23994587
[TBL] [Abstract][Full Text] [Related]
16. NZ28-induced inhibition of HSF1, SP1 and NF-κB triggers the loss of the natural killer cell-activating ligands MICA/B on human tumor cells.
Schilling D; Kühnel A; Tetzlaff F; Konrad S; Multhoff G
Cancer Immunol Immunother; 2015 May; 64(5):599-608. PubMed ID: 25854583
[TBL] [Abstract][Full Text] [Related]
17. Varicella-Zoster Virus and Herpes Simplex Virus 1 Differentially Modulate NKG2D Ligand Expression during Productive Infection.
Campbell TM; McSharry BP; Steain M; Slobedman B; Abendroth A
J Virol; 2015 Aug; 89(15):7932-43. PubMed ID: 25995251
[TBL] [Abstract][Full Text] [Related]
18. Critical role of MHC class I-related chain A and B expression on IFN-alpha-stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection.
Jinushi M; Takehara T; Kanto T; Tatsumi T; Groh V; Spies T; Miyagi T; Suzuki T; Sasaki Y; Hayashi N
J Immunol; 2003 Feb; 170(3):1249-56. PubMed ID: 12538683
[TBL] [Abstract][Full Text] [Related]
19. Natural killer cells inhibit hepatitis C virus expression.
Li Y; Zhang T; Ho C; Orange JS; Douglas SD; Ho WZ
J Leukoc Biol; 2004 Dec; 76(6):1171-9. PubMed ID: 15339939
[TBL] [Abstract][Full Text] [Related]
20. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
